Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the efficacy and safety of acotiamide in patients with esophagogastric junction outflow obstruction: study protocol for an investigator-initiated, multi-center, randomized, double-blind, placebo-controlled phase II trial.
Esaki M, Ihara E, Manabe N, Kawami N, Iwakiri K, Akiyama J, Kuribayashi S, Uraoka T, Ogino H, Chinen T, Misumi A, Watanabe H, Suzuki M, Kishimoto J, Ogawa Y. Esaki M, et al. Among authors: kishimoto j. Trials. 2023 Jul 18;24(1):459. doi: 10.1186/s13063-023-07468-w. Trials. 2023. PMID: 37464279 Free PMC article.
An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing's Syndrome and Autonomous Cortisol Secretion.
Oda S, Ashida K, Uchiyama M, Sakamoto S, Hasuzawa N, Nagayama A, Wang L, Nagata H, Sakamoto R, Kishimoto J, Todaka K, Ogawa Y, Nakanishi Y, Nomura M. Oda S, et al. Among authors: kishimoto j. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3865-e3880. doi: 10.1210/clinem/dgab450. J Clin Endocrinol Metab. 2021. PMID: 34143883 Clinical Trial.
Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity.
Arima M, Inoue H, Nakao S, Misumi A, Suzuki M, Matsushita I, Araki S, Yamashiro C, Takahashi K, Ochiai M, Yoshida N, Hirose M, Kishimoto J, Todaka K, Hasegawa S, Kimura K, Kusuhara K, Kondo H, Ohga S, Sonoda KH. Arima M, et al. Among authors: kishimoto j. BMJ Open. 2021 Jul 27;11(7):e047003. doi: 10.1136/bmjopen-2020-047003. BMJ Open. 2021. PMID: 34315793 Free PMC article.
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Kimura K, et al. Among authors: kishimoto j. EBioMedicine. 2022 Jun;80:104069. doi: 10.1016/j.ebiom.2022.104069. Epub 2022 May 20. EBioMedicine. 2022. PMID: 35605429 Free PMC article. Clinical Trial.
Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial.
Hosokawa K, Abe K, Kishimoto J, Kobayakawa Y, Todaka K, Tamura Y, Tatsumi K, Inami T, Ikeda N, Taniguchi Y, Minatsuki S, Murohara T, Yasuda S, Fukuda K, Tsutsui H. Hosokawa K, et al. Among authors: kishimoto j. BMJ Open. 2022 Jul 19;12(7):e061225. doi: 10.1136/bmjopen-2022-061225. BMJ Open. 2022. PMID: 37070473 Free PMC article.
Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study).
Chihara Y, Yamada T, Uchino J, Tamiya N, Kaneko Y, Kishimoto J, Takayama K. Chihara Y, et al. Among authors: kishimoto j. Transl Lung Cancer Res. 2019 Dec;8(6):1086-1090. doi: 10.21037/tlcr.2019.11.19. Transl Lung Cancer Res. 2019. PMID: 32010586 Free PMC article.
Safety and efficacy of brilliant blue g250 (BBG) for lens capsular staining: a phase III physician-initiated multicenter clinical trial.
Hisatomi T, Enaida H, Yoshida S, Hirakata A, Ohji M, Nishida K, Kubota T, Ogata N, Matsui T, Kimura K, Sonoda KH, Uchiyama M, Kishimoto J, Todaka K, Nakanishi Y, Ishibashi T. Hisatomi T, et al. Among authors: kishimoto j. Jpn J Ophthalmol. 2020 Sep;64(5):455-461. doi: 10.1007/s10384-020-00763-y. Epub 2020 Aug 18. Jpn J Ophthalmol. 2020. PMID: 32809075
3-day intervention program for family members of hikikomori sufferers: A pilot randomized controlled trial.
Kubo H, Urata H, Sakai M, Nonaka S, Kishimoto J, Saito K, Tateno M, Kobara K, Fujisawa D, Hashimoto N, Suzuki Y, Honda Y, Nakao T, Otsuka K, Kanba S, Kuroki T, Kato TA. Kubo H, et al. Among authors: kishimoto j. Front Psychiatry. 2023 Jan 9;13:1029653. doi: 10.3389/fpsyt.2022.1029653. eCollection 2022. Front Psychiatry. 2023. PMID: 36699498 Free PMC article.
261 results